AbD Serotec

This story has been updated from a previous version to include comments from Bio-Rad's earnings call.

NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced yesterday that it has signed a definitive agreement to acquire antibody manufacturer AbD Serotec for €53 million ($69.7 million) in cash.

Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.

Morphosys announced that its AbD Serotec division has signed an agreement with the Moredun Research Institute and the University of Edinburgh's Roslin Institute to develop reagents for veterinary research.

The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.